This report was first published by Endpoints News. To see the original version, click here
Roche is teaming up with Jiangsu, China-based Qyuns Therapeutics for a bispecific antibody that could potentially treat asthma, COPD and other respiratory diseases.
To start working with Qyuns, Roche is delivering $70 million upfront, the Hong Kong-listed biotech disclosed in a regulatory filing on Wednesday. It could dole out up to $995 million more in biobucks if a preclinical-stage antibody called QX031N makes it through clinical development and onto the market, according to the filing.
您已閱讀33%（583字），剩余67%（1171字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。